
usd feb pm et
summari compani global leader pharmaceut medic devic consum health
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan stock trade
jnj sale grew yoy mark
materi slowdown growth
first nine month main culprit
slowdown
sale slow first
nine month yoy expect
challeng year growth
pharmaceut prostat cancer drug zytiga
gener sale
begin lose materi market share new
gener approv late
also mark sharp slowdown medic
devic sale total yoy
growth first month
first declin consum sale
total sinc slowdown end
year especi concern given
invest acquisit sinc end
think mani larg
purchas predic deliv higher
sustain growth achiev
reuter publish stori alleg
disclos fda
asbesto sometim found
babi powder date back
vehement deni alleg
defend court relat case
histor enjoy import brand
power across consum medic
devic segment combin revenu
custom trust import success
see potenti meaning damag
brand howev stem
recent news report alleg knew
decad babi powder could contain
asbesto whether claim ultimatley
merit think materi risk
issu appear news
custom lose trust brand
segment superior
long-term growth prospect view
particularli due robust drug pipelin
nearli phase trial recent fda file
underway like difficult year
pharmaceut growth howev due
biosimilar gener competit key
drug remicad zytiga combin
target price ep
estim -- five-year averag
forward price-to-earnings see potenti neg
sale growth potenti risk
pipelin failur neg news coverag
risk assess reflect benefit health
care product larg immun econom
cycl earn overli reliant
singl product categori also enjoy competit
advantag owe substanti financi resourc
divers product offer global sale capabl
strength balanc often unpredict
natur drug innov pipelin patent
challeng well advers legal rule
brought health care product develop
case also damag brand associ
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview johnson johnson rank one largest diversifi health care
firm world product span pharmaceut medic devic consum product
segment sale develop market wide rang synthet
biolog drug import therapeut area immunolog drug
total revenu treat autoimmun diseas like crohn diseas psoriasi rheumatoid
arthriti oncolog drug treat tumor form cancer neurosci drug
disord like depress schizophrenia cardiovascular drug treat high blood
pressur prevent blood clot stroke
pharmaceut product highli complex difficult develop often consum sever year
billion invest dollar found ineffect late stage human trial fail pass
regulatori approv hurdl fda larg major research develop
spend acquisit spend goe toward pharmaceut
develop acquisit compani promis pipelin drug frequent
reinvest new drug need keep drug pipelin full continu churn
market drug replac lost sale exist drug eventu lose market share
similar compet drug becom obsolet due new treatment
uncertainti involv develop market success pharmaceut largest risk
earn view billion invest dollar risk never produc
profit drug compet version drug success patent challeng court
competitor cut short success drug profit lifespan one recent exampl best-sel
drug remicad sale biolog drug began lose sale due biosimilar akin
gener version biolog drug approv approv biosimilar remicad
sale fell like drop even compet
biosimilar enter market anoth top-sel drug zytiga sale held patent
initi valid lengthi patent court battl sever gener competitor right
market gener form zytiga begin late accordingli expect zytiga sale fall
precipit
medic devic segment sale sell wide rang health care product includ
wound care surgic instrument implant hip knee replac spinal implant like
pharmaceut medic devic segment also depend invest develop innov
consum segment sale sell wide varieti person care product one might find
groceri store retail pharmaci includ over-the-count medicin adult skin hair care
product babi care oral care first aid women health nutrit supplement consum
segment includ major brand-nam like band-aid listerin johnson babi care line neutrogena
aveeno skin hair care product mani well-known over-the-count medicin like tylenol pepcid
sudaf
brand-nam reput critic import success consum segment view
consum product often face sever low-pric compet product trust brand name make
big differ sale especi come health care product one put bodi
love one bodi
due import brand power consum trust think alleg reuter stori
publish decemb could meaning neg impact consum segment
well medic devic segment lesser extent report alleg disclos
fda asbesto sometim found babi powder date back
vehement deni alleg defend court relat case well put forth
major public relat campaign defend safeti babi powder product regardless
think report like come next year subject whether report
merit think materi risk issu news less trust
consum brand
corpor strategi oper compani sell product across globe
despit size highli innov view seek maintain leadership posit
aggress fund new product develop spend total billion repres
sale major devot drug develop januari nearli
late-stag clinic drug trial underway fda file review process mani trial
expand treatment indic exist drug also expect compani launch least
seven novel drug end
although intern growth key object also pursu strateg acquisit total
june acquir billion
retain actelion market drug mainli treat hypertens late stage compound actelion
discoveri stage oper spun new compani own option
financi trend total revenu grown repres
compound annual growth rate compound-annual-growth-rate period adjust ep grew
compound-annual-growth-rate grown ep faster sale mainli margin
improv adjust oper margin improv around also
alloc materi capit share repurchas dividend combin total year
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv nda activ
food drug administr fda --
posit brand drug maker
repres lion share
improv gener profit margin
competit appear moder
overal posit view somewhat temper
expect lower growth overal
expect strong pace nda continu
next year aid continu robust
growth invest led major brand drug
compani banner year nda
fda new drug approv
repres surg approv compar
mani
new drug littl competit
provid tailwind brand drug
maker strong growth spend
primari driver novel approv uptick
industri increas
estim pace anoth year
growth septemb
growth mark rapid acceler
averag annual growth
side sub-industri
outlook earn growth gener
maker posit closer neutral fda
gener approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side think lower competit
start impact note gener
approv tick vs
first materi declin least six
year also note move
averag gener applic lead
think anoth sign
mitig competit allow
moder gener deflat
modest improv gener profit margin
year ahead
anoth boost gener maker
record year fda first-gener approv
experienc
first-gener typic enter
market materi lower price
brand-nam counterpart allow
quick market share gain accordingli
major increas first-gener provid
revenu tailwind gener maker next
mitig posit outlook
sub-industri expect slower
prescript volum growth next
year strong gain health-insur
popul driven solid employ
growth view
think gain harder come
 approach full employ
remov tailwind prescript
volum growth assum
slower growth health plan roll gener
mean slower growth prescript volum
versu rise composit
drop
year date januari pharma
slip gain
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
juri st loui missouri rule
asbestos-ovarian cancer link relat babi powder juri award
billion women claim develop ovarian cancer use
babi powder shower-to-show anoth talc-bas product allegedli
contamin asbesto deni babi powder contamin
asbesto appeal rule although see case lead
numer addit case relat asbesto babi powder link believ
mani year case reach final conclus
talc/babi powder lawsuit file sever result juri decis
see overhang share howev compani
success appeal abl overturn rule
et cfra keep buy opinion share johnson johnson
keep target peer
ep estim faster growth ep vs in-lin
estim sale fx benefit rose
growth forecast cost rose higher expect
growth broad-bas domest sale intern sale
fx benefit consum sale rose pharmaceut
sale aid contribut actelion acquisit rose
medic devic sale rose encourag stabil
medic devic robust pharmaceut sale driven increas
oncolog sale strong uptak darzalex imbruvica zytiga
note sale remicad fell due higher discount rebat amid
biosimilar competit see continu weak throughout also
announc plan increas spend due benefit
analyst research note compani news
et cfra keep hold opinion share johnson johnson
rais target price
ep estim -- slightli five-year averag price-to-earnings multipl
expect modest slowdown growth next year ep vs
slightli consensu rais ep estim
cy revenu growth
modest acceler aid roughli acquisit
execut sinc start despit materi sale growth
slow yoy sharp slowdown yoy first month
much slowdown relat slow pharma sale total
grew yoy vs first month mainli driven
gener competit key oncolog drug zytiga whose growth slow
expect free cash flow return capit remain
strong think like slowdown growth warrant conserv
pm et cfra lower opinion johnson johnson share hold
buy drop target
ep estim -- five-year averag forward price-to-earnings expect
neg impact recent alleg cancer-caus asbesto certain
product maintain ep estim lower
report surfac today alleg
disclos fda asbesto sometim found babi powder
ingredi date back vehement deni either
way expect signific damag unfold valuabl brand name
consum product medic devic built decad
consum medic devic segment gener profit brand
name accompani consum trust critic success see
today news potenti impact sale everyth babi shampoo
prosthet hip given elev risk longer feel share
attract recent price /colin scarola
lower target peer
averag ep estim view exist drug portfolio
pipelin posit ep vs slightli forecast
lower ep estim slower growth
medic devic segment initi ep estim modest
sale growth quarter yoy led pharma segment
increas oncolog group particularli strong perform within pharma
grow sale yoy total expect pharma continu
drive growth come year especi stelara imbruvica
darzalex increas sale yoy improv
margin mix think robust demand drug overcom potenti
gener competit zytiga total sale next year slower growth
medic devic consum segment grew sale yoy
et cfra keep buy opinion share johnson johnson
keep target slightli peer
forward ep estim view pipelin
posit see continu robust drug sale adjust ep vs
ahead view rais ep estim
sale includ fx benefit rose pharmaceut
medic devic consum product sale rose
world-wide fell partli declin babi
care segment due retail stock reduct discount anticip
babi care product relaunch acquisit actelion contribut
pharmaceut sale growth pharma sale driven rise
stelara sale rise invega sustenna robust rise
oncolog segment howev expect remicad sale fell due
biosimilar competit reiter plan file launch new
blockbust drug /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
